Loading
Hemoglobinopathies and Related Disorders / CRISPR and Genetic Engineering · Journal article
JCO Oncology Practice · August 19, 2026
A consensus or society position rather than new primary data.
This is a clinical implementation guidance article summarizing the translational status of exagamglogene autotemcel, the first approved CRISPR-based therapy, as a curative-intent treatment for severe sickle cell disease and transfusion-dependent β-thalassemia. The source documents durable clinical benefits (freedom from severe vaso-occlusive crises in SCD; transfusion independence in TDT) and outlines critical infrastructure, barriers, and multidisciplinary coordination required for safe and equitable delivery. For oncology, CRISPR remains investigational with early feasibility signals in relapsed/refractory hematologic and selected solid tumors.
Journal article. Eligible patients with severe sickle cell disease and transfusion-dependent β-thalassemia for hemoglobinopathies; patients with relapsed or refractory B-cell malignancies, T-cell malignancies, AML, multiple myeloma, and selected solid tumors for oncology applications.. Intervention: Exagamglogene autotemcel: ex vivo CRISPR-Cas9 editing of autologous CD34+ hematopoietic stem and progenitor cells to reactivate fetal hemoglobin..
Exagamglogene autotemcel produces durable freedom from severe vaso-occlusive crises in SCD and sustained transfusion independence in TDT following ex vivo CRISPR-Cas9 editing of autologous CD34+ hematopoietic stem and progenitor cells. Successful clinical implementation requires structured referral, candidacy assessment, organ function review, mobilization and collection, centralized manufacturing, pharmacokinetic-guided myeloablative conditioning, transplant-level supportive care, fertility preservation, psychosocial support, and prolonged surveillance. Key implementation barriers include stem cell collection, conditioning-related toxicity, cost, reimbursement friction, and persistent inequities in access.
Source is guidance, not primary efficacy or safety data; specific effect sizes, confidence intervals, and p-values for clinical outcomes not reported. Quantified incidence or severity of conditioning-related toxicity, cost, reimbursement friction, and access inequities not provided.
Clinicians in hematology, oncology, and cellular therapy should recognize exagamglogene autotemcel as an established curative option for eligible hemoglobinopathy patients, but implementation requires multidisciplinary coordination, infrastructure investment, and attention to equity and long-term safety. CRISPR-based approaches in malignancy remain experimental and require careful patient selection and registry participation.
Expert consensus and implementation guidance on clinical translation of CRISPR-based therapy in hemoglobinopathies with established regulatory approval, addressing delivery, patient selection, and barriers to practice integration.
As stated by the source record.
Clinicians in hematology, oncology, and cellular therapy should recognize exagamglogene autotemcel as an established curative option for eligible hemoglobinopathy patients, but implementation requires multidisciplinary coordination, infrastructure investment, and attention to equity and long-term safety. CRISPR-based approaches in malignancy remain experimental and require careful patient selection and registry participation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Exagamglogene autotemcel, the first clustered regularly interspaced short palindromic repeats (CRISPR)-based gene-editing therapy to enter clinical practice, has established genome editing as a curative-intent option for eligible patients with severe sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT). Ex vivo CRISPR-Cas9 editing of autologous CD34-positive hematopoietic stem and progenitor cells to reactivate fetal hemoglobin has produced durable freedom from severe vaso-occlusive crises in SCD and sustained transfusion independence in TDT. This approach offers a donor-independent alternative to allogeneic hematopoietic stem-cell transplantation without graft rejection or graft-versus-host disease. Hemoglobinopathies, therefore, provide the first clinically validated delivery model for CRISPR therapeutics. Successful implementation, however, requires more than editing efficacy. It depends on structured referral, candidacy assessment, organ function review, mobilization and collection, centralized manufacturing, pharmacokinetic-guided myeloablative conditioning, transplant-level supportive care, fertility preservation, psychosocial support, and prolonged surveillance coordinated among primary hematologists and cellular therapy programs. Key barriers include stem cell collection, conditioning-related toxicity, cost, reimbursement friction, and persistent inequities in access. Long-term follow-up and registry participation are necessary to evaluate outcomes beyond pain crises, identify late toxic effects, and compare real-world effectiveness across gene editing, gene addition, and allogeneic transplantation. In oncology, CRISPR-based therapy remains investigational, with early clinical feasibility demonstrated in relapsed or refractory B-cell malignancies, T-cell malignancies, AML, multiple myeloma, and selected solid tumors. For hematologists, oncologists, and transplant and cellular therapy programs, the central challenge is to integrate CRISPR into practice with the rigor required for any high-risk curative therapy: careful patient selection, disciplined delivery, and long-term accountability.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.